Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Emergent BioSolutionsEBS -1.43%65 Cash Ratio is 1.14 as of Jun. 2026, which is 2% below its 10-year median of 1.16. GuruFocus rates EBS with a GF Score™ of 65/100 and a GF Value™ of $5.47 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 961 Drug Manufacturers companies, Emergent BioSolutions ranks better than 65.35% on this metric.
Emergent BioSolutions has a Cash Ratio of 1.14. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Emergent BioSolutions's Cash Ratio or its related term are showing as below:
EBS'
s Cash Ratio Range Over the Past 10 Years
Min: 0.11 Med: 1.16 Max: 4.52
Current: 1.14
During the past 13 years, Emergent BioSolutions's highest Cash Ratio was 4.52. The lowest was 0.11. And the median was 1.16.
EBS's Cash Ratio is ranked better than 65.35% of 961
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs EBS: 1.14
Emergent BioSolutions (NYSE:EBS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emergent BioSolutions Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Emergent BioSolutions's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emergent BioSolutions (EBS) has a Cash Ratio of 1.14 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Emergent BioSolutions and its competitors. This is near median its historical median of 1.16. Over the past decade, Emergent BioSolutions' Cash Ratio has ranged from 0.11 to 4.52. According to the industry distribution chart, Emergent BioSolutions ranks #333 out of 961 companies in the Drug Manufacturers industry, placing it in the top 34.7%.
Is Emergent BioSolutions' Cash Ratio too high?
Emergent BioSolutions' current Cash Ratio of 1.14 is near median its 10-year median of 1.16. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 4.52. The Drug Manufacturers industry median Cash Ratio is 0.60. Emergent BioSolutions' value of 1.14 is 90% above this industry median. Based on the distribution chart, Emergent BioSolutions ranks #333 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Emergent BioSolutions has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Cash Ratio compare to EOLS and ELTP?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #333 out of 961 companies for Cash Ratio. This puts Emergent BioSolutions in the upper half of its industry. The industry median Cash Ratio is 0.60. Emergent BioSolutions' value of 1.14 is 90% above this benchmark. Historically, Emergent BioSolutions' own Cash Ratio has ranged from 0.11 to 4.52 over the past decade. While the company's 10-year median is 1.16 vs. the industry median of 0.60, Emergent BioSolutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Emergent BioSolutions's current Cash Ratio of 1.14 is 90% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Emergent BioSolutions and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emergent BioSolutions's current Cash Ratio is 1.14, which is near median its own 10-year median of 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (EBS) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.47, compared to a current price of $4.82 — trading 11.9% below its estimated fair value. The current Cash Ratio is 1.14, which is near median its 10-year median of 1.16 and 90% above the Drug Manufacturers industry median of 0.60. Emergent BioSolutions' overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Emergent BioSolutions (EBS), the current Cash Ratio is 1.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Emergent BioSolutions (EBS) Overvalued in 2026?
Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be undervalued.
The current stock price of $4.82 is trading 11.9% below its estimated GF Value™ of $5.47.
GuruFocus considers Emergent BioSolutions to be Modestly Undervalued.
Key valuation signals for EBS:
Cash Ratio: 1.14 (near median its 10-year median of 1.16)
GF Value™: $5.47 vs. price of $4.82 (11.9% below fair value)
Industry Position: 90% above the Drug Manufacturers median (#333 of 961)
No single metric tells the full story. See the EBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
65GF Score
Get the complete analysis for EBS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBS has been successfully added to your 
